MX2017013156A - Metodos para tratar enfermedades. - Google Patents

Metodos para tratar enfermedades.

Info

Publication number
MX2017013156A
MX2017013156A MX2017013156A MX2017013156A MX2017013156A MX 2017013156 A MX2017013156 A MX 2017013156A MX 2017013156 A MX2017013156 A MX 2017013156A MX 2017013156 A MX2017013156 A MX 2017013156A MX 2017013156 A MX2017013156 A MX 2017013156A
Authority
MX
Mexico
Prior art keywords
methods
treating diseases
asthma
antibodies
treatment
Prior art date
Application number
MX2017013156A
Other languages
English (en)
Inventor
Chadham Nivens Michael
Arndt-Schmitz Kirsten
BERTON Alix
Quast Karsten
Schlepuetz Marco
Visvanathan Sudha
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2017013156A publication Critical patent/MX2017013156A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere generalmente a métodos para el tratamiento de enfermedades respiratorias, tales como asma, mediante el uso de anticuerpos anti-IL-23A.
MX2017013156A 2015-04-14 2016-04-13 Metodos para tratar enfermedades. MX2017013156A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562147281P 2015-04-14 2015-04-14
US201562220385P 2015-09-18 2015-09-18
PCT/US2016/027263 WO2016168282A1 (en) 2015-04-14 2016-04-13 Methods of treating diseases

Publications (1)

Publication Number Publication Date
MX2017013156A true MX2017013156A (es) 2018-02-21

Family

ID=55911058

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017013156A MX2017013156A (es) 2015-04-14 2016-04-13 Metodos para tratar enfermedades.

Country Status (16)

Country Link
US (4) US20160304602A1 (es)
EP (3) EP3685856A1 (es)
JP (1) JP2018512422A (es)
KR (1) KR20170135972A (es)
CN (1) CN107530425A (es)
AU (1) AU2016247921A1 (es)
BR (1) BR112017018574A2 (es)
CA (1) CA2977534A1 (es)
CL (1) CL2017002304A1 (es)
EA (1) EA201792282A1 (es)
HK (2) HK1243937A1 (es)
IL (1) IL253847A0 (es)
MX (1) MX2017013156A (es)
PH (1) PH12017501872A1 (es)
SG (1) SG11201708399WA (es)
WO (1) WO2016168282A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018135328A (ja) * 2017-02-21 2018-08-30 地方独立行政法人青森県産業技術センター ＴＮＦα産生抑制剤
CN113621558A (zh) * 2021-09-08 2021-11-09 上海万何圆生物科技有限公司 一种新鲜肝组织切片的体外培养方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
ATE135397T1 (de) 1988-09-23 1996-03-15 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
ATE196606T1 (de) 1992-11-13 2000-10-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
CN101252951B (zh) 2005-06-30 2011-12-21 森托科尔公司 抗il-23抗体、组合物、方法和用途
WO2007024846A2 (en) 2005-08-25 2007-03-01 Eli Lilly And Company Anit-il-23 antibiodies
PL1931710T3 (pl) 2005-08-31 2017-06-30 Merck Sharp & Dohme Corp. Przeciwciała anty-il-23 skonstruowane techniką inżynierii genetycznej
EP1971366B1 (en) 2005-12-29 2014-07-30 Janssen Biotech, Inc. Human anti-il-23 antibodies, compositions, methods and uses
AU2007260787A1 (en) * 2006-06-13 2007-12-21 Zymogenetics, Inc IL-17 and IL-23 antagonists and methods of using the same
SI2426144T1 (sl) 2007-02-23 2019-02-28 Merck Sharp & Dohme Corp. Umetno proizvedena anti-IL23P19 antitelesa
EP3456740A1 (en) * 2010-11-04 2019-03-20 Boehringer Ingelheim International GmbH Anti-il-23 antibodies
US9078894B2 (en) * 2011-02-04 2015-07-14 Ab Science Treatment of severe persistant asthma with masitinib
EP4039275A1 (en) * 2012-05-03 2022-08-10 Boehringer Ingelheim International GmbH Anti-il-23p19 antibodies

Also Published As

Publication number Publication date
PH12017501872A1 (en) 2018-02-26
SG11201708399WA (en) 2017-11-29
EP3685856A1 (en) 2020-07-29
BR112017018574A2 (pt) 2018-04-17
US20180009887A1 (en) 2018-01-11
EA201792282A1 (ru) 2018-04-30
KR20170135972A (ko) 2017-12-08
WO2016168282A1 (en) 2016-10-20
CN107530425A (zh) 2018-01-02
HK1243937A1 (zh) 2018-07-27
US20190359701A1 (en) 2019-11-28
CA2977534A1 (en) 2016-10-20
US20160304602A1 (en) 2016-10-20
EP3283109A1 (en) 2018-02-21
IL253847A0 (en) 2017-09-28
JP2018512422A (ja) 2018-05-17
AU2016247921A1 (en) 2017-08-31
HK1255728A1 (zh) 2019-08-23
EP3391905A1 (en) 2018-10-24
US20180334501A1 (en) 2018-11-22
CL2017002304A1 (es) 2018-05-18

Similar Documents

Publication Publication Date Title
JOP20200192A1 (ar) أجسام مضادة لـ tigit
PH12017501077A1 (en) Compositions and methods for antibodies targeting bmp6
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
PH12016501441A1 (en) Chimeric alkaline phosphate-like proteins
MX370480B (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades.
MX2018008105A (es) Compuestos inhibidores de metaloenzima.
PH12018500578A1 (en) Methods of treating inflammatory diseases
MX369623B (es) Compuestos biciclicos fusionados para el tratamiento de enfermedades.
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
EA201890185A1 (ru) Способы лечения опосредованных гепсидином нарушений
MX2020006237A (es) Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4.
PH12017500853A1 (en) Cd44v6-derived cyclic peptides for treating cancers and angionesesis related diseases
MY195000A (en) Method for the treatment of neurological disease
PH12016501613B1 (en) Pyrazines modulators of gpr6
MX2017012342A (es) Compuestos biciclicos fusionados para el tratamiento de enfermedades,.
MX2019004182A (es) Proceso para la fabricacion de 2,6-dimetil-5-hepten-1-al.
PH12017501872A1 (en) Methods of treating diseases
PH12018500339A1 (en) Lysobactin for use in the treatment of bovine mastitis
MX2018003040A (es) Metodos para el tratamiento de formas recurrentes de esclerosis multiple.